Genentech Agreements

7 December 2021
1st agreement with Genentech

Starpharma will design and synthesize a number of DEP® dendrimer conjugates and provide them to Genentech for testing and characterisation. The initial term of the agreement is 18 months. This Research Agreement covers the research phase of the project and any next steps would be discussed at the conclusion of the project.


So we are now pass the 18 month period (7th June) by more than 6 weeks

Update please


27th June 2022
2nd agreement with Genentech

Expanded exploratory Research Agreement will utilise Starpharma’s proprietary DEP® technology to evaluate further drug conjugates

This agreement has exactly the same terms as the first one and is in addition to the current DEP® research program signed in December 2021

While we are on this subject, I refer to Merck and Chase Sun agreements

Starpharma has a collaboration with Chase Sun. Initial project was for the development of DEP® conjugates for an anti-infective drug, with an ability to add additional programs in other therapeutic areas The deal was signed in August 2020. Almost 3 years later and all that has been said is the following

Starpharma’s DEP® partnership with Chase Sun continues to progress well (April quarterly 2023)

One would expect an update after nearly 3 years


Merck

First agreement dates back to 12 February 2021. Under the agreement, MSD were conducting a preclinical
research evaluation of dendrimer based Antibody Drug Conjugates (ADCs) utilising Starpharma’s proprietary DEP® technology. If my memory serves me correctly there was no initial term of agreement specified for this. So almost two and a half years later, according to Starpharma, it is still ongoing. Merck must have tons of candidates by now

In August 2022, almost 18 months later an additional agreement was entered into with an initial 12 month term. This Research Agreement covers a research project. What that means is left to interpretation. The initial term of this second agreement is coming to a close on 10th August 2023

If I was to speculate, this could be an inflection point for Merck to enter a human clinical trial


AstraZeneca

Currently there are 2 human trials in Phase 1/2 being conducted to test AZD0466. One of these trials is in a partial clinical halt.

A further indication is yet be announced to enter trials



In early June 2019.......Starpharma entered into an option agreement with AstraZeneca to develop an enhanced version of an AstraZeneca currently marketed oncology drug which generated USD 1 Billion plus (blockbuster) last financial year (2018).

Under this agreement, Starpharma conducted preclinical testing of the DEP® version of the AstraZeneca oncology product.

At any time from the signing of this agreement and for a defined period after the completion of this testing, AstraZeneca were able t0 exercise its option and licence the DEP® drug candidate for clinical and commercial development.

If AstraZeneca exercises the option, an option exercise fee of US$5 million is payable to Starpharma, as well as industry standard development and commercialisation milestones and escalating royalties on sales.

In the event AstraZeneca does not exercise its option to licence the DEP® drug candidate within the defined period, Starpharma has the option to license the rights to develop and commercialise this DEP® drug either itself or through a sub-licensee with milestones and royalties paid to AstraZeneca upon commercialisation of the resultant DEP® product.

So almost 4 years later one would expect the defined period to have expired

And what have we learnt from our CEO regarding an update on this.

It is on foot (AGM November 2022)

Frustration is an understatement in regards to providing transparency to us shareholders

And it all began in earnest from December 2018 more than 4 and a half years ago